Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C08L-005/08
A61L-024/00
A61L-024/04
A61L-024/06
A61L-024/08
A61L-024/10
A61L-026/00
A61L-027/16
A61L-027/18
A61L-027/20
A61L-027/22
A61L-027/24
A61L-027/50
A61L-027/54
A61L-027/58
C08L-033/12
C08L-035/04
C08L-067/04
C08L-083/04
A61K-031/575
출원번호
US-0454135
(2017-03-09)
등록번호
US-10226550
(2019-03-12)
발명자
/ 주소
Savage, Paul B.
Genberg, Carl
Bracken, Ronald
출원인 / 주소
BRIGHAM YOUNG UNIVERSITY
대리인 / 주소
Workman Nydegger
인용정보
피인용 횟수 :
0인용 특허 :
52
초록▼
This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, a
This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.
대표청구항▼
1. A soft tissue filler composition for injection into soft tissue, comprising: a biologically compatible soft tissue filler material in the form of a liquid, gel, paste, or viscous material so as to be syringe-injectable into soft tissue at a treatment site, wherein the soft tissue filler compositi
1. A soft tissue filler composition for injection into soft tissue, comprising: a biologically compatible soft tissue filler material in the form of a liquid, gel, paste, or viscous material so as to be syringe-injectable into soft tissue at a treatment site, wherein the soft tissue filler composition comprises a tissue adhesive; and0.1% to 30% (w/w) of one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the biologically compatible soft tissue filler material so that, when injected into soft tissue, the soft tissue filler material can form a bolus having a reservoir of CSA compounds incorporated into and distributed within a matrix of the soft tissue filler material and provide effective time release of the one or more CSA compounds from the soft tissue filler material. 2. The soft tissue filler composition of claim 1, wherein the tissue adhesive comprises cyanoacrylate. 3. The soft tissue filler composition of claim 2, wherein the tissue adhesive includes an octyl or butyl ester of cyanoacrylate. 4. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more syringe-injectable bioabsorbable materials. 5. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more of hyaluronic acid, collagen, hydroxyapatite mineral, or poly-l-lactic acid in syringe-injectable form. 6. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more of silicone or polymethylmethacrylate in syringe-injectable form. 7. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition comprises botox. 8. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds are included in the soft tissue filler composition in an amount ranging from about 0.5% to about 20% (w/w). 9. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds independently provide to the soft tissue filler composition at least one of anti-microbial effect, anti-inflammatory effect, or increased rate of tissue wound healing. 10. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds includes CSA-131. 11. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds includes one or more sulfonic acid addition salts. 12. The soft tissue filler composition of claim 11, wherein the one or more sulfonic acid addition salts includes 1,5-naphthalenedisulfonic acid salt. 13. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition provides protection against biofouling longer than a soft tissue filler composition not having one or more incorporated CSA compounds. 14. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition provides enhanced anti-inflammatory activity as compared to a soft tissue filler composition not having one or more incorporated CSA compounds. 15. A method for controlling microbial growth on an injected soft tissue filler composition and/or at a treatment site at which the soft tissue filler composition has been injected, comprising: providing a syringe-injectable soft tissue filler composition in the form of a liquid, gel, paste, or viscous material and comprising a biologically compatible soft tissue filler material and 0.1% to 30% (w/w) of one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the soft tissue filler material, wherein the soft tissue filler composition is a tissue glue, and wherein the tissue glue is injected so as to embolize a blood vessel or occlude a fistula;injecting the soft tissue filler composition by syringe into soft tissue at the treatment site; andthe one more CSA compounds killing one or more microbes contacting the soft tissue filler composition. 16. The method of claim 15, wherein the one or more CSA compounds include CSA-131, and wherein the CSA-131 is provided as a sulfonic acid addition salt. 17. The method of claim 15, wherein the syringe-injectable soft tissue filler comprises one or more of a bioabsorbable material, hyaluronic acid, collagen, hydroxyapatite mineral, poly-l-lactic acid, or silicone. 18. A method for controlling microbial growth at a wound site, comprising: providing a tissue adhesive composition comprising a biologically compatible cyanoacrylate adhesive material and one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the cyanoacrylate adhesive material;injecting and/or applying the tissue adhesive composition onto tissue at the wound site so as to close a wound, embolize a blood vessel, or occlude a fistula; andthe tissue adhesive composition killing one or more microbes contacting the tissue adhesive composition. 19. The method of claim 18, wherein the one or more CSA compounds comprise a 1,5-naphthalenedisulfonic acid salt of CSA-131.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (52)
Savage, Paul B., Aerosols incorporating ceragenin compounds and methods of use thereof.
Hansen Richard E. (Roswell GA) Rippl Carl G. (Woodstock GA) Midkiff David G. (Alpharetta GA) Neuwirth Joseph G. (Cumming GA), Antimicrobial absorbent food pad.
Darouiche Rabih O. (Houston TX) Raad Issam (Houston TX), Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical i.
Hibbs, Michael; Altman, Susan J.; Jones, Howland D. T.; Savage, Paul B., Biofouling-resistant ceragenin-modified materials and structures for water treatment.
Dunn Michael J. ; Bergren Michael S. ; Hardee Gregory E. ; Shephard Kenneth Paul ; Chao Robert S. ; Havens Jeffrey L., Crystalline ceftiofur free acid.
Laurencin Cato T. (Somerville MA) Lucas Paul A. (Macon GA) Syftestad Glenn T. (Sacramento CA) Domb Abraham (Baltimore MD) Glowacki Julianne (Jamaica Plan MA) Langer Robert S. (Newton MA), Delivery system for controlled release of bioactive factors.
Di Domenico Edward D. (Anoka MN) Hobot Christopher M. (Tonka Bay MN) Stokes Kenneth B. (Minneapolis MN) Coury Arthur J. (St. Paul MN) Doan Phong D. (Shoreview MN) Sandstrom Richard D. (Scandia MN), Medical electrical lead with polymeric monolithic controlled release device and method of manufacture.
Eisen Drore (6720 E. Beechlands Dr. Cincinnati OH 65237), Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter.
Garlich Joseph R. (Lake Jackson TX) Masterson Tipton T. (Lake Jackson TX) Simon Jaime (Angleton TX) Hegde Vidyadhar B. (Indianapolis IN), Oral compositions for suppressing mouth odors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.